Drug Profile


Alternative Names: 5c8; 5c8 humanised monoclonal antibody; Anti-CD154 monoclonal antibody; Anti-CD40 ligand antibody; Anti-CD40 ligand monoclonal antibody; Anti-CD40 ligand monoclonal antibody 5c8; Anti-gp39 monoclonal antibody - Biogen; Antova; BG 9588; CD40 ligand monoclonal antibody - Biogen; hu5c8; Humanised CD40 ligand antibody/5c8; T cell-B cell activation molecule; T-BAM

Latest Information Update: 07 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Haemophilia A; Immune thrombocytopenic purpura; Multiple sclerosis; Renal transplant rejection; Systemic lupus erythematosus

Most Recent Events

  • 28 Aug 2001 A study has been added to the adverse events and Transplant Rejection therapeutic trials sections
  • 22 Aug 2001 Anti-CD40 ligand monoclonal antibody 5c8 is now called Ruplizumab
  • 28 Apr 2000 A clinical study has been added to the therapeutic trials section of haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top